Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence
NCT ID: NCT00688298
Last Updated: 2020-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2004-05-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There are currently no studies that investigate the pre-pubic delivery approach in the United States. However, the largest series of cases in Europe using the pre-pubic system was done by Ulmsten (published in the European Journal of Obstetrics and Gynecology and Reproductive Biology) 107 (2003) 205-207, titled " Pre-Pubic tension free vaginal tape application: an alternative to classic tension free vaginal tape application in selected patients with SUI."
The primary objective of this study is to evaluate the feasibility of using a pre-pubic approach to the placement of a mid-urethral vaginal mesh.
* Demonstrate the mesh can be properly placed in the mid-urethra using a pre-pubic approach;
* Assess the performance of the delivery device by measuring the ease of use, technical complexity, and instrument difficulties
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Female patients Greater than or 18 years of age, diagnosed with Stress Urinary Incontinence (SUI).
Prefyx PPS™ System
A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
Advantage ™ System
The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prefyx PPS™ System
A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
Advantage ™ System
The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing and able to comply with the study procedures and provide written informed consent to participate in the study
* Diagnosed with genuine SUI confirmed by urodynamic evaluation (urodynamic evaluations performed in the past 6 months are acceptable) and documented in the source documents as in patients charts, physicians notes, nurses notes, hospital records, etc.
* If the patient has an overactive bladder, the condition must be a minor component of the patient's disorder demonstrated by the urodynamic testing. This is a physician
* discretion for inclusion or exclusion in the study.
* Patients are willing to complete (PFDI-short form 20) and PISQ-12 at baseline, 3 months, 6 months and 12 months post-operatively.
* Patient has documented SUI classification and the degree of hypermobility and/ or intrinsic sphincter abnormality (Q-Tip test). Confirm the patient's SUI diagnosis using one or more of the following procedures:
* Vaginal exam
* Cough provocation test
* Cystoscopic exam
* Patients must have a negative urine culture
* Patients' bladder capacity of 350cc or more
* Document voiding diary pre- and post-operatively
* Document post-void residual (PVR) of equal to or less than 100cc
* Patients that require a regional, general anesthesia or monitored anesthesia
* Pad test on baseline that demonstrate 5 grams or greater urine loss
* Patients are mentally competent and able to understand all study requirements
* Patients agree to read and sign the informed consent form prior to any study related procedures (screening/ baseline visit)
Exclusion Criteria
* Patients who, are in the investigator's opinion, mentally or legally incapacitated, or unable to read or understand written material, thereby preventing informed consent
* Patients who have participated in an investigational study (medical device or drug) within 30 days of study entry that may impact analysis of this device or have previously participated in the current trial
* Patients who are pregnant, lactating, or planning future pregnancies
* Patients with Diabetes Mellitus type I or II
* Patients with vesicourethral reflex, upper urinary tract obstruction, spastic bladder, or detrouser muscle instability
* Patient treated with corticosteriod or immunosuppresant agents within 90 days pre-operatively except for patients treated with inhaled steroids for the treatment of asthma
* Patients with compromised immune systems
* Patients with any acute cystitis or urethritis
* Patients that had previous urinary incontinence procedures
* Patients that had a previous radiation to the pelvis
* Patients with coagulopathy and/ or currently on anticoagulant medications
* Patients with known or suspected hypersensitivity to the mesh
* Patients that complain of pelvic pain and/ or dyspareunia
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston Scientific Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Boston Scientific
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Walsh, M.D.
Role: STUDY_DIRECTOR
Boston Scientific Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North Shore University Hospital
Manhasset, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U0299
Identifier Type: -
Identifier Source: org_study_id